Letrozole Tablet, Film Coated
Product Images NDC 50090-3474

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 50090-3474). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903474)

Label for Letrozole 2.5 mg film-coated tablets, oral dosage form, manufactured by A-S Medication Solutions. The label includes product number 6792-0, lot number, storage instructions at 77 degrees Fahrenheit, and a package count of 90 tablets. Distributed by D-S Medication Solutions in Libertyville, IL.*

FDA Label Image

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Fig1)

A survival curve graph comparing Letrozole and Tamoxifen treatments over 72 months. The y-axis represents survival proportion from 0.0 to 1.0, and the x-axis shows time in months. The solid line represents Letrozole, while the dashed line represents Tamoxifen. Tabulated patient data, including numbers at risk and event counts for both treatments, are visible above and below the graph.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Fig2)

A line chart comparing progression-free survival over time (months) between Letrozole tablets 2.5 mg and Tamoxifen 20 mg. The y-axis represents progression-free proportion (0 to 1), and the x-axis shows time in months up to 60, illustrating trends for both medications.*

FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (Letrozole Fig3)

A survival curve chart comparing the proportion of patients alive over time (months) between two treatments: letrozole and tamoxifen. The x-axis represents time in months up to 60, and the y-axis shows the proportion alive from 0 to 1. The chart includes two lines labeled 'letrozole 1st' (solid) and 'tamoxifen 1st' (dashed), depicting survival trends for each treatment group.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Fig4)

A survival curve line chart depicting time to progression in days for different treatment groups including Letrozole Tablet 0.5 mg, Letrozole Tablet 2.5 mg, and another group labeled MA. The x-axis represents time to progression in days, while the y-axis shows the survival probability, decreasing over time.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Fig5)

A survival curve chart showing time to progression in days for different treatment groups involving Letrozole tablets at 0.5 mg, Letrozole tablets at 2.5 mg, and a group labeled AG. The vertical axis represents survival probability, and the horizontal axis represents time to progression in days, up to around 1000 days.*

FDA Label Image

Letrozole Structural Formula (Letrozole Str)

Chemical structure of letrozole, depicting a triazole ring connected to two benzonitrile groups, each containing a cyano (CN) substituent on the benzene rings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.